Диссертация (1154359), страница 40
Текст из файла (страница 40)
2015.-№52(1). -р. 1-11.467.Mosebach, K. institutional change or political stalemate? Health carefinancing reform in Germany / K. Mosebach // Eurohealth. – 2006. - Vol.12, N 4. – P. 11-14.255468.Multifactor dimensionality reduction analysis to elucidate the cross-talk between one-carbon and xenobiotic metabolicn pathways in multidisease models. Naushad S.M., Sowganthika S., Ramaiah M.J., Rao D.N.Molecular biology reports.
– 2015 - Vol: 42 (7). P: 1211-1224. DOI:10.1007/s11033-015-3856-z.469.Neutel, J. Improving patient compliance: a major goal in the man-agement of hypertension / J. Neutel, D. Smith // J. Clin. Hypertens. –2003. – N 5. – P. 127-132.470.Niemi, M. Glyburide and glimepiride pharmacokinetics in subjectwith different CYP2C9 genotypes/ M.Niemi,I.Cascorbi//Clin.Pharmacol Therap. – 2012. - Vol.72 – P. 326-332.471.Nitric oxide synthase 1 is partly compensating for nitric oxide syn-thase 3 deficiency in knock – out mice and is elevated in murine and human cirrhosis.
Neef M., Sagesser H., Shaw S., Koshy A., Reichen J. Liverinternational. – 2004. - Vol: 24(4). P. 345-353. DOI: 10.1111/j.14783231.2004.0933.x.472.NOKC. Nasjonalt Kunnskapssenter for Helsetjenesten: Еrsrapport2004 [Norwegian Knowledge Centre for Health Services: Activity Report2004] Oslo, 2005. Electronic Links:http://www.nokc.no.473.Nolte, E. The transformation of the East German healthcare systemLessons for enlargement?/ / E. Nolte // Eurohealth. – 2002. - Vol. 8, N 4.– P. 42-44.474.OECD.
Health technologies and decision making. - Paris, OECDPublishing.2005.ElectronicLinks:http://dx.doi.org/10.1787/9789264016224-en.475.Olsson, S. National Pharmacovigilance Systems / S. Olsson. - 2ndedn // Uppsala Monitoring Crntre. Drug Safety. 1998. - №19. Р. 1-10.256476.Olsson, S. The Role of the WHO Programme on international drugmonitoring in coordinating wordwide drug safety efforts / S. Olsson //Drug Safety. – 1998.
– Vol. 19. – P. 1-10.477.Osokogu OU. Pharmacoepidemiological safety studies in children: asystematic review / OU Osokogu, J Dukanovic, C Ferrajolo [et al.]. //Pharmacoepidemiology and Drug Safety. 2016 .- №25. Р. 861–870.478.Palmer, S.C., et al., Erythropoiesis-stimulating agents for anaemia inadults with chronic kidney disease: a network meta-analysis. TheCochrane database of systematic reviews, 2014. 12: p.590.PMID:25486075 DOI: 10.1002/14651858.CD010590.pub2.479.Patient adherence with amlodipine, lisinopril, or valsartan therapy ina usual-care setting / J. Wogen, C.A. Kreilick, R.C.
Livornese [et al. ] // JManag Care Pharm. – 2003. – Vol. 9 (5). – P. 424–429.480.Patient-reported and physician-estimated adherence to HAART / R.Murri, A. Ammassari, M.P. Trotta [et al.] // J Gen Intern Med. – 2004. –Vol. 19. – P. 1104–1110.481.Park D.W., Ahn J.M., Song H.G., et al. Differential prognostic im-pact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention.
// Am Heart J. 2013. - №165. - р. 34-42.482.Perleth, M. A short history of health technology assessment in Ger-many / M. Perleth, B. Gibis, B. Gohlen // Int J Technol Assesment HealthCare. – 2009. – Vol. 25 (1). – P. 178-181.483.Persistent use of evidence-based pharmacotherapy in heart failure isassociated with improved outcomes / G.
Gislason, J. Rasmussen, S.Abildstrom [et al.] // Circulation. – 2007. – Vol. 116. – P. 737-744.484.Personalized Medicine // Current opinion in Molecular Theraputics.– Basel: Current Drugs. – 2002. - Vol 4(6). - P. 548-558.257485.Pharmacogenomics / Edited by Rothstein M.A. -New Jersey:Willyliss, 2003. - P.
368.486.Polymorphism of Nitric Oxide Synthase 1 Affects the Clinical Phe-notypes of Ischemic Stroke in Korean Population / SD Yoo, JS Park, DHYun [et al.] // Ann Rehabil Med. – 2016. – Vol.40(1). – P. 102-110.https://doi.org/10.5535/arm.2016.40.1.102487.Polymorphisms in NOS3, MTHFR, APOB and TNF-α Genes andRisk of Coronary Atherosclerotic Lesions in Iranian Patients / MMHeidari, M Khatami, M Hadadzadeh [et al.] // Research in CardiovascularMedicine. – 2016.
– Vol.5(1):e29134. doi:10.5812/cardiovascmed.29134.488.Practical approach to determining costs and frequency of adversedrug events in a health care network / B.L. Senst, L.E. Achusim, R.P.Genest [et al.] // Am. J. Health Syst. Pharm. - 2001. - Vol. 58. - P. 11261158.489.Preskorn, S. The potential for clinically significant drug-drug interac-tions involving the CYP2D6 system/ S. Preskorn, R.
Shah [et al.] //J.Psychiatr Practice. - 2007. -Vol. 13 (1). – P. 5-12.490.Prospective Observational Studies to Assess Comparative Effective-ness: The ISPOR Good Research Practices Task Force Report / M.L. Berger, N. Dreyer, R. Anderson [et al.] // Value Health. – 2012. – Vol.
15(2).– P. 217-247.491.Rank reversal in indirect comparisons / E.C. Norton, M.M. Miller,J.J. Wang [et al.] // Value Health. – 2012. – Vol. 15(8). – P. 1137-1177.492.Rasmussen, J. Relationship between adherence to evidencebasedpharmacotherapy and long-term mortality after acute myocardial infarction/ J. Rasmussen, A. Chong, D. Alter // JAMA. – 2014. – Vol. 297.
– P. 177186.258493.Reappraisal of European guidelines on hypertension management: aEuropean Society of Hypertension Task Force document / G. Mancia, St.Laurent, E. Agabiti-Rosei [et al.] // J. Hypertens. – 2009. - Vol. 27. - P.2121-2158.494.Regitz-Zagrosek functional relevance of the human angiotensin IItype 1 and type 2 receptor genes on left ventricular (lv) structure / R.E.Schmieder, J. Erdmann, K. Hilgers [et al.] // Journal of Hypertension.
–1999. – 17 (3). – P. 81.495.Relationship of Genetic Polymorphisms of Aldosterone SynthaseGene Cytochrome P450 11B2 and Mineralocorticoid Receptors with Coronary Artery Disease in Taiwan / C-H Chou, K-C Ueng, S-F Yang [et al.]// International Journal of Medical Sciences. – 2016. – Vol.13(2). – P.
117123. doi:10.7150/ijms.13862.496.Relationship of blood pressure control to adherence with antihyper-tensive monotherapy in 13 managed care organizations / T. Bramley, P.Gerbino, B.J. Nightengale [at al.] // Manag. Care Pharm. – 2016. – Vol.12. – P. 239–245.497.Relative Effectiveness Assessment of Pharmaceuticals: Similaritiesand Differences in 29 Jurisdictions / S. Kleijnen, F. George, S. Goulden[et al] // Value In Health. – 2012. – Vol.
15. – P. 9-960.498.Relative efficacy of drugs: an emerging issue between regulatoryagencies and third-party payers / H.G. Eichler, A. Bloechl-Daum, E.Abadie [et al.] // Nat Rev Drug Discov. – 2010. – Vol. 9. – P. 277-291.499.Rendic, S. Summary of information on human CYP enzymes: human450 metabolism data./S. Rendic // Drug Metab Rev. – 2002. – Vol. 34 (12). – P. 83-448.500.Renin Genetic Polymorphism in Heart Failure Patients / D. Pop, A-V. Sitar-Tăut, L.
Procopciuc [et al.] // ROM. J. INTERN. MED. – 2015. –Vol.53, №1. – P. 39–45259501.Rice, Thomas The United States Health System: Transition TowardsUniversal Coverage / T. Rice // Eurohealth Incorporating Euro Observer. –2013. - Vol. 19, N. 3. - P. 41 – 43.502.Roberts M., Russell L.B., Paltiel A.D., Chambers M., McEwan P.,Krahn M; ISPOR-SMDM modeling good research practices, Task Forceconceptualizing a model: a report of the ISPOR-SMDM Modeling GoodResearch Practices Task Force-2. Med Decis Making. 2012. № 5. Р. 678–689.503.Rose, O.
Priority Setting and Influential Factors on Acceptance ofPharmaceutical Recommendations in Collaborative Medication Reviewsin an Ambulatory Care Setting - Analysis of a Cluster Randomized Controlled Trial (WestGem-Study) / O. Rose, H. Mennemann , C. John [etal.]. // PLoS One. – 2016. - №11(6). – р.156-304.504.Saab, Y.B. Associations of renin- angiotensin-aldosteron systemgenes with blood pressure changes and hypertension incidence. Americanjournal of hypertension. – 2015.
Том: 28.- (11). P. 1310-1315. DOI:10.1093/ajh/hpv033.505.Samani, N.J. The personal genome-the future of personalized medi-cine? / N.J. Samani, M. Tomaszewski, H. Schunkert // Lancet. – 2013,May1. – Vol. 375(9725). – P.1497-1505.506.Schoenemann, J. Unerwunschte Arzneimittelwirkungen in der klinik/ J. Schoenemann, K.H. Munter, S. Enayati.Kashani // Dtsch. Med.Wochenschr. – 1998.
– Vol. 123 (15). – P. 448-452.507.Schousboe, L.P. Correct documentation of drug prescriptions / L.P.Schousboe, O. Tandrup // Ugeskr. Laeger. – 1999. – Vol. 161(31). – P.4389-4392.260508.Schroeder, K. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials / K. Schroeder, T.
Fahey, S. Ebrahim // Arch. Intern.Med. - 2004. – Vol. 164. – P. 722-754.509.Schroeder, K. Interventions for improving adherence to treatment inpatients with high blood pressure in ambulatory settings / K. Schroeder, T.Fahey, S. Ebrahim // The Cochrane Database of Systematic Reviews. The Cochrane Collaboration: John Wiley and Sons, Ltd., 2006.
- N4.PMID: 15106262 DOI: 10.1002/14651858.CD004804.510.Sekino, K. Effect of the single CYP2C9*3 allele on pharmacokineticand pharmacodinamic of losartan in healthy Japanese subjects/K.Sekino,T. Kubota [et al.] // Eur J Clin Pharmacol. - 2003. -Vol.59(8-9). – P. 589592.511.Shnayder N.A., Dmitrenko D.V., Veselova O.F., Bochanova E.N.Role of pharmacogenetics in prevention of vaproate-induced adverse drugreactions from central neurous system.
// Abstract Book International Congress on Neuroscince / Edited by A.B. Salmina, M.M. Petrova, E.A.Pozhilenkova..-Krasnoyarsk, KrasSMU.- 2014.- P.91.512.Simpson, R. The effects of adherence and persistence on clinical out-comes in patients treated with statins: a systematic review / R.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
